Who
Robert J. Hombach
Director
Company insider
Files Form 4 as: Director, Embecta; Director, Seaport Therapeutics; Director, BioMarin Pharmaceutical; Director, Henry Schein; Director, Aptinyx; Director, CarMax; EVP. CFO and COO, Baxalta; Corporate Vice President, Baxter International.
In numbers
- Trades disclosed
- 111
- Buys
- 11
- Sells
- 1
- Bought
- $2.1M
- Sold
- $3.5M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 1 Sep 2010
- Last trade
- 12 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 13 Aug 2026 | EMBC EmbectaMedical Devices | SEC FORM 4 Bought | $224K45,000 at $4.97 | filing |
| 12 Aug 2026filed 13 Aug 2026 | EMBC EmbectaMedical Devices | SEC FORM 4 Bought | $224K45,000 at $4.97 | filing |
| 22 Jun 2026filed 24 Jun 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Bought | $236K13,000 at $18.14 | filing |
| 22 Jun 2026filed 24 Jun 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Bought | $236K13,000 at $18.14 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,258 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,258 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,577 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,577 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | EMBC EmbectaMedical Devices | SEC FORM 4 Code A | —22,841 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | EMBC EmbectaMedical Devices | SEC FORM 4 Code A | —22,841 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,650 at $0.00 | filing |
| 4 Mar 2025filed 6 Mar 2025 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,844 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | EMBC EmbectaMedical Devices | SEC FORM 4 Code A | —13,839 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —4,720 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | EMBC EmbectaMedical Devices | SEC FORM 4 Code A | —11,455 at $0.00 | filing |
| 23 May 2023filed 24 May 2023 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —4,190 at $0.00 | filing |
| 9 Feb 2023filed 10 Feb 2023 | EMBC EmbectaMedical Devices | SEC FORM 4 Code A | —6,979 at $0.00 | filing |
| 26 May 2022filed 31 May 2022 | Aptinyxoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Venus Concept (NASDAQ:VERO) vs. Embecta (NASDAQ:EMBC) Head-To-Head ComparisonEMBC · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Robert J. Hombach; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.